Per Persson News Today

Norhisham (Nori) Iskhandar brings a depth of AV market knowledge and a wealth of experience in product development and business management.

Aristotle’s postulate that “nature abhors a vacuum” could be used to explain why X-ray photoelectron spectroscopy (XPS) has not found routine application in the analysis of biological samples.

10.01.2022 - Press release (MAR)Malmö, Sweden, January 10, 2022 Acarix appoints US based Helen Ljungdahl Round as new CEO The Board of Acarix AB (publ) has today appointed Helen Ljungdahl Round as new Chief Executive Officer, with immediate effect. Helen is ...

Press release (MAR)Malmö, Sweden, October 27, 2021 Acarix granted US CPT reimbursement code for CADScor System The editorial panel of the American Medical Association (AMA) today approved the Category

Press releaseMalmö, Sweden, August 27, 2021 Initial Dan-NICAD II results presented today at ESC Study confirms excellent rule-out capacity of CADScor, almost 50% of intermediate

Acarix AB: Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 publication. The long term Prognostic data from the Dan-NICAD 1 trial was first presented at the ESC Congress in Sept...

Acarix AB: A strong ending of an eventful year A strong ending of an eventful year The fourth quarter contributed strongly to our overall performance in 2020, with the market approval for CADScor from the US Food and Drug Administration (FDA) as the outstanding achievement. Extract from CEO Per Perssons message to the End Year Report. Fourth quarter 2020 compared with same period 2019 During the fourth quarter, 22 CADScorSystem (10, of which 4 to clinical trials) and 1,420 (1,500, of which 840 ...

Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor ®System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of heart failure. The study, with in total 199 patients at two sites in Denmark, included t...

Acarix AB: Positive preliminary data from Acarixs exploratory heart failure study SEISMO Positive preliminary data from Acarixs exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of hear...